Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion
Massimo Filippi(Vita-Salute San Raffaele University), María Trojano(University of Bari Aldo Moro), Maria Pia Amato(University of Florence), Matilde Inglese(New York University), Paolo Gallo(University of Padua), Francesco Patti(University of Catania), Carlo Pozzilli(Sapienza University of Rome), Diego Centonze(University of Rome Tor Vergata), Paolo Preziosa(Vita-Salute San Raffaele University), Claudio Gasperini(Nini Hospital)
Cited by 187
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Multiple sclerosis
|Nature Reviews Disease Primers|2018|1.4k